Abstract
Multiparameter flow cytometry has become an indispensable tool for the diagnosis and classification of acute myeloid leukemia (AML). The basic method relies on the unique ability to detect immunophenotypic abnormalities on discrete subpopulations. The primary roles in the initial assessment of AML are to determine the immaturity of the leukemic population, define the lineage and the immunophenotypic aberrancies in blasts, and identify characteristic immunophenotypic features to predict important recurrent cytogenetic and genetic abnormalities and prognosis. The established immunophenotypic profile, a baseline “fingerprint,” is used for follow-up assessment of residual disease. This chapter provides an overview of procedures for specimen processing, staining, and immunophenotyping of AML and describes our strategy for data analysis supplemented with illustrative case examples.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Swerdlow SH, Campo E, Harrris NL et al (eds) (2008) World Health Organization classification of tumors of haematopoietic and lymphoid tissues, 4th edn. WHO Press, Geneva, Switzerland
Craig FE, Foon KA (2008) Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111:3941–3967
Kaleem Z, Crawford E, Pathan MH et al (2003) Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med 127:42–48
Gorczyca W, Sun ZY, Cronin W et al (2011) Immunophenotypic pattern of myeloid populations by flow cytometry analysis. Methods Cell Biol 103:221–266
Khoury H, Dalal BI, Nantel SH et al (2004) Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21). Mod Pathol 17:1211–1216
Kita K, Nakase K, Miwa H et al (1992) Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 80:470–477
Paietta E, Goloubeva O, Neuberg D et al (2004) A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry B Clin Cytom 59:1–9
Lin P, Hao S, Medeiros LJ et al (2004) Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis. Am J Clin Pathol 121:402–407
Kern W, Voskova D, Schoch C et al (2004) Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104:3078–3085
San Miguel JF, Vidriales MB, Lopez-Berges C et al (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98:1746–1751
Campana D, Coustan-Smith E (1999) Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 38:139–152
Borowitz MJ, Devidas M, Hunger SP et al (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's oncology group study. Blood 111:5477–5485
Borowitz MJ, Wood BL, Devidas M et al (2015) Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s oncology group study AALL0232. Blood 126:964–971
Araki D, Wood BL, Othus M et al (2015) Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol 34:329–336
Buccisano F, Maurillo L, Spagnoli A et al (2010) Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 116:2295–2303
Kalina T, Flores-Montero J, van der Velden VH et al (2012) EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26:1986–2010
Wood B (2006) 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 130:680–690
Stelzer GT, Shults KE, Loken MR (1993) CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 677:265–280
Borowitz MJ, Guenther KL, Shults KE et al (1993) Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 100:534–540
Harrington AM, Olteanu H, Kroft SH (2012) A dissection of the CD45/side scatter “blast gate”. Am J Clin Pathol 137:800–804
Xu Y, McKenna RW, Wilson KS et al (2006) Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation. Leukemia 20:1321–1324
Wood BL (2003) Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med 27:551–575
Kussick SJ, Wood BL (2003) Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med 127:1140–1147
Fuda F, Chen W (2014) Lineage determination in mixed phenotype acute leukemia: response to Marcondes et al. Cytometry B Clin Cytom 86:150–151
Al-Mawali A, Gillis D, Lewis I (2009) The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 131:16–26
Kern W, Haferlach C, Haferlach T et al (2008) Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 112:4–16
Chen W, Konoplev S, Medeiros LJ et al (2009) Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer 115:5481–5489
Kussick SJ, Stirewalt DL, Yi HS et al (2004) A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia 18:1591–1598
Rakheja D, Konoplev S, Medeiros LJ et al (2012) IDH mutations in acute myeloid leukemia. Hum Pathol 43:1541–1551
Yang DT, Greenwood JH, Hartung L et al (2005) Flow cytometric analysis of different CD14 epitopes can help identify immature monocytic populations. Am J Clin Pathol 124:930–936
Karandikar NJ, Aquino DB, McKenna RW et al (2001) Transient myeloproliferative disorder and acute myeloid leukemia in down syndrome. An immunophenotypic analysis. Am J Clin Pathol 116:204–210
Wang L, Peters JM, Fuda F et al (2015) Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype. Cytometry B Clin Cytom 88:244–252
Haferlach T, Kohlmann A, Klein HU et al (2009) AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia 23:934–943
Acknowledgments
Dr. Franklin Fuda is gratefully acknowledged for critical reading and commenting the content of this chapter. The authors also thank the medical technologists in the Clinical Flow Cytometry laboratory at the University of Texas Southwestern Medical Center for their technical assistance.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Chen, W., Luu, H.S. (2017). Immunophenotyping by Multiparameter Flow Cytometry. In: Fortina, P., Londin, E., Park, J., Kricka, L. (eds) Acute Myeloid Leukemia. Methods in Molecular Biology, vol 1633. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7142-8_4
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7142-8_4
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7140-4
Online ISBN: 978-1-4939-7142-8
eBook Packages: Springer Protocols